The ongoing US government shutdown is delaying critical jobs and inflation reports, creating an information vacuum for investors and the Federal Reserve.
Combination therapy approval for small cell lung cancer offers a new standard of care and a bullish signal for the pharmaceutical sector.
First-of-its-kind maintenance therapy approved for extensive-stage small cell lung cancer, a historically difficult-to-treat malignancy.
The designation for ALTO-101 targets cognitive impairment, a debilitating aspect of schizophrenia with no currently approved treatments.
Investor demand drives prices to new all-time highs as Bitcoin balances on exchanges plummet to a six-year low.
Fiscal paralysis in Washington delays key economic data while the central bank cuts rates to support a cooling economy, creating a complex outlook for investors.
The U.S. Food and Drug Administration has accepted for review the company's New Drug Application for Relacorilant, a treatment for Cushing's syndrome.
Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.